Gabather AB
Developing novel GABAA receptor drugs for neuropsychiatric disorders.
GABA | ST
Overview
Corporate Details
- ISIN(s):
- SE0010869552 (+1 more)
- LEI:
- 549300VLUOMD0TE1O093
- Country:
- Sweden
- Address:
- FORSKARGATAN 20 J, 151 36 Södertälje
- Website:
- https://gabather.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Gabather AB is a clinical-stage pharmaceutical company, founded in 2014, that develops novel therapeutics for neuropsychiatric disorders. The company's approach focuses on proprietary drug candidates that modulate the GABAA receptor system to restore balance in the brain and enhance cognitive function. Its primary focus areas include anti-psychotics, anti-depressants, anxiolytics, analgesics, and cognition-enhancing treatments for conditions such as Alzheimer's disease. Gabather's lead drug candidate, GT-002, has completed Phase I clinical trials, showing excellent pharmacokinetics and a strong safety profile. The company's development projects are based on over a decade of research from Lund University and the Research Institute of Biological Psychiatry in Roskilde.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Gabather AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Gabather AB
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Gabather AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
